Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by SABBOBCATon Sep 23, 2019 3:49pm

318 Views

Post# 30156049

Listing Timeline

Today marks the 6 week name from the Nasdaq listing PR so the company should have approval back from the exchange. Now it is only a matter of time before the company lists. Their external guidance is 60 days, so a little over 2 weeks and we should be trading in the US. If there are any delays then the company should be upfront as I would argue that it's material info from a liquidity perspective. GLTA and in the mean time, keep an eye on Edgar for the filings.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages